Changes Ahead For Pfizer, But Don't Expect A "Big Bang," Read Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer turns in flat first-quarter sales and keeps investors waiting for more details on plans for potential spinouts or restructuring.